Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

Z. Kerényi, Holger Samer, Rachel James, Ying Yan, Murray Stewart

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Aim: To compare the efficacy of combination therapy using rosiglitazone (8mg per day) and glibenclamide (7.5mg per day) with upward titration of glibenclamide as monotherapy (maximum dose=15mg per day) in reducing HbA 1c levels over 26 weeks in patients with type 2 diabetes mellitus (T2DM). Methods: Three hundred and forty patients with T2DM inadequately controlled (FPG ≥7.0 and ≤15.0mmol/l) on glibenclamide 7.5mg per day were randomised to either additional treatment with rosiglitazone 8mg per day or up-titration of the glibenclamide dose (maximum dose=15mg per day). Results: After 26 weeks, treatment with rosiglitazone combination reduced HbA 1c by 0.81% (P

Original languageEnglish
Pages (from-to)213-223
Number of pages11
JournalDiabetes Research and Clinical Practice
Volume63
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

rosiglitazone
Glyburide
Type 2 Diabetes Mellitus
Therapeutics

Keywords

  • Combination therapy
  • Glibenclamide
  • Rosiglitazone
  • Sulphonylureas
  • Thiazolidinediones

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. / Kerényi, Z.; Samer, Holger; James, Rachel; Yan, Ying; Stewart, Murray.

In: Diabetes Research and Clinical Practice, Vol. 63, No. 3, 03.2004, p. 213-223.

Research output: Contribution to journalArticle

@article{0311daed715b44639085fff1516c9fd0,
title = "Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus",
abstract = "Aim: To compare the efficacy of combination therapy using rosiglitazone (8mg per day) and glibenclamide (7.5mg per day) with upward titration of glibenclamide as monotherapy (maximum dose=15mg per day) in reducing HbA 1c levels over 26 weeks in patients with type 2 diabetes mellitus (T2DM). Methods: Three hundred and forty patients with T2DM inadequately controlled (FPG ≥7.0 and ≤15.0mmol/l) on glibenclamide 7.5mg per day were randomised to either additional treatment with rosiglitazone 8mg per day or up-titration of the glibenclamide dose (maximum dose=15mg per day). Results: After 26 weeks, treatment with rosiglitazone combination reduced HbA 1c by 0.81{\%} (P",
keywords = "Combination therapy, Glibenclamide, Rosiglitazone, Sulphonylureas, Thiazolidinediones",
author = "Z. Ker{\'e}nyi and Holger Samer and Rachel James and Ying Yan and Murray Stewart",
year = "2004",
month = "3",
doi = "10.1016/j.diabres.2003.09.009",
language = "English",
volume = "63",
pages = "213--223",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

AU - Kerényi, Z.

AU - Samer, Holger

AU - James, Rachel

AU - Yan, Ying

AU - Stewart, Murray

PY - 2004/3

Y1 - 2004/3

N2 - Aim: To compare the efficacy of combination therapy using rosiglitazone (8mg per day) and glibenclamide (7.5mg per day) with upward titration of glibenclamide as monotherapy (maximum dose=15mg per day) in reducing HbA 1c levels over 26 weeks in patients with type 2 diabetes mellitus (T2DM). Methods: Three hundred and forty patients with T2DM inadequately controlled (FPG ≥7.0 and ≤15.0mmol/l) on glibenclamide 7.5mg per day were randomised to either additional treatment with rosiglitazone 8mg per day or up-titration of the glibenclamide dose (maximum dose=15mg per day). Results: After 26 weeks, treatment with rosiglitazone combination reduced HbA 1c by 0.81% (P

AB - Aim: To compare the efficacy of combination therapy using rosiglitazone (8mg per day) and glibenclamide (7.5mg per day) with upward titration of glibenclamide as monotherapy (maximum dose=15mg per day) in reducing HbA 1c levels over 26 weeks in patients with type 2 diabetes mellitus (T2DM). Methods: Three hundred and forty patients with T2DM inadequately controlled (FPG ≥7.0 and ≤15.0mmol/l) on glibenclamide 7.5mg per day were randomised to either additional treatment with rosiglitazone 8mg per day or up-titration of the glibenclamide dose (maximum dose=15mg per day). Results: After 26 weeks, treatment with rosiglitazone combination reduced HbA 1c by 0.81% (P

KW - Combination therapy

KW - Glibenclamide

KW - Rosiglitazone

KW - Sulphonylureas

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=0942300619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942300619&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2003.09.009

DO - 10.1016/j.diabres.2003.09.009

M3 - Article

C2 - 14757293

AN - SCOPUS:0942300619

VL - 63

SP - 213

EP - 223

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -